Vyome Cuts Third-Quarter Loss to $930,000 as It Advances Drug Development Programs

0
14
Krishna Gupta

CAMBRIDGE, Mass.–Vyome Holdings Inc. reported a substantial reduction in its third-quarter net loss as the clinical-stage biopharmaceutical company continued developing its lead drug candidate, VT-1953, and preparing for further discussions with the U.S. Food and Drug Administration.

The company reported a net loss of $930,325 for the quarter ended September 30, 2026, compared with $8.6 million during the same period last year. Loss per share attributable to common shareholders narrowed to $0.13 from $3.06 a year earlier.

The improvement largely reflected the absence of significant merger-related expenses recorded in the third quarter of 2025, when the company incurred approximately $7.7 million in transaction costs. Changes in the weighted-average number of outstanding shares also contributed to the year-over-year reduction in loss per share.

Quarterly revenue increased to $57,998 from $34,627 in the corresponding period last year.

Vyome ended September with approximately $6.96 million in cash and cash equivalents, up from $4.98 million at the end of 2025. Total assets stood at $8.61 million, while stockholders’ equity reached $6.55 million.

Operating expenses declined to approximately $1.05 million from $8.59 million a year earlier. Research and development spending totaled $409,831, while selling, general and administrative expenses were $635,410.

Krishna Gupta, Chairman of Vyome Holdings, said the company remained focused on advancing its primary development program while controlling expenses.

“During the third quarter, Vyome continued to concentrate resources on the development of its lead program, VT-1953, while maintaining financial discipline and progressing selected activities across its pipeline. The Company ended September with approximately $7.0 million in cash and cash equivalents. Our emphasis remains on advancing defined development priorities and managing capital carefully.”

Vyome’s lead investigational therapy, VT-1953, is a topical gel being developed to treat symptoms associated with malignant fungating wounds, a serious complication that can occur in patients with advanced cancer.

The company is continuing formulation development, manufacturing preparations and clinical planning for the treatment. Following written feedback from the FDA on its pre-Investigational New Drug briefing package, Vyome is preparing additional scientific and clinical information for a planned Type C meeting with the agency.

Venkat Nelabhotla, President and CEO of Vyome, said advancing VT-1953 remains the company’s central priority.

“Our immediate priority remains VT-1953. During the quarter, we continued product development, CMC activities, clinical development planning, and preparatory work with prospective GMP manufacturing partners. Following the FDA’s written feedback on our pre-IND briefing package, we have continued assembling the scientific, CMC, and clinical information required to support further discussion with the FDA through a Type C meeting before advancing our proposed clinical development program.”

The FDA has also requested additional information and clarification concerning Vyome’s application for Orphan Drug Designation for VT-1953. The company is preparing a response as the regulatory review continues.

Previously reported results from an investigator-initiated Phase 2 study of VT-1953 showed statistically significant improvements in wound odor, the impact of odor on patients’ daily lives and lesion pain. No treatment-emergent adverse events were reported in that study.

Vyome is also progressing VT-1908, an investigational topical ophthalmic treatment being developed for anterior uveitis, an inflammatory eye condition.

In October, the U.S. Patent and Trademark Office issued a Notice of Allowance covering patent claims related to formulations and methods of use associated with VT-1908.

“We are also reviewing the FDA’s request for additional information and clarification relating to our VT-1953 Orphan Drug Designation application and preparing our response, including any necessary amendment. In parallel, formulation and CMC work continued for our VT-1908 topical ophthalmic program. We remain focused on the progression of our investigational programs and on selective opportunities within immuno-inflammatory disease, while making development and capital allocation decisions based on available data,” concluded Nelabhotla.

During the quarter, Vyome appointed Jerry Leonard as Chief Financial Officer, effective September 1.

The company also announced that its Co-Founder and Director, Dr. Shiladitya Sengupta, was promoted to Professor of Medicine at Harvard Medical School in October.

For the first nine months of 2026, Vyome reported a net loss of $2.64 million, compared with $9.2 million during the corresponding period in 2025. Revenue for the nine-month period totaled $116,544, down from $283,163 a year earlier.

Vyome, which focuses on developing treatments for immuno-inflammatory and rare diseases, continues to concentrate its financial resources on its clinical pipeline as it works toward additional regulatory milestones.

Leave A Reply

Please enter your comment!
Please enter your name here